| Literature DB >> 35400120 |
Vanessa-Meletia Bala1, Maria Mitsogianni1, Konstantinos Laschos1, Evangelia Pliakou1, Eirini Lazaridi1, Dimitra-Ioanna Lampropoulou1, Gerasimos Aravantinos1.
Abstract
BRAF/MEK inhibitors are considered standard of care in the treatment of advanced BRAF-mutated malignant melanoma, and have been, in rare cases, associated with granulomatous reactions, mostly limited to skin lesions. The present study reported the case of a patient with metastatic melanoma developing a sarcoid-like reaction manifesting as asymptomatic mediastinal and right hilar lymphadenopathy while on antineoplastic therapy with dabrafenib and trametinib. To the best of our knowledge, this is the first reported case of isolated lymphadenopathy as a manifestation of drug-induced sarcoid-like reaction under dabrafenib and trametinib. Overall, only 17 other cases of granulomatosis have been reported in the literature. Although uncommon, such reactions should be considered in the differential diagnosis of lymph node enlargement, and distinguishing them from tumor progress is important and can be challenging in clinical practice.Entities:
Keywords: BRAF/MEK inhibitors; dabrafenib; melanoma; sarcoidosis; trametinib
Year: 2022 PMID: 35400120 PMCID: PMC8985069 DOI: 10.3892/mco.2022.2532
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450